BIO-TECH SYSTEMS, INC.,
founded in 1980, specializes in market research and strategic
planning, where technological and scientific insight is
important. This focuses on emerging fields of technology where
it is necessary to make accurate forecasts of future market
demand and communicate effectively with many levels of
management and end-users. One objective is to assess
technological risk and target new products and services
effectively in order to generate the best market response.
One distinguishing feature of Bio-Tech's reports is that the author will provide a generous amount of technical support and consultation at no additional cost to assist the readers in interpreting the contents of the report and utilizing the information in their own applications. This substantially enhances the value of the report and also allows access to Bio-Tech's extensive database and technical resources.
The
methodology for collecting market data and generating market
forecasts involves many information sources developed over 20
years in this field, concentrating on diagnostic and therapeutic
radiopharmaceuticals, radiotherapy and immunotherapy products,
brachytherapy, PET imaging, contrast agents, and interventional
cardiology. This benefits from analytical insight and extensive
experience with these products, as well as a large internal
database that is regularly updated. BIO-TECH SYSTEMS has
developed effective models that have been refined extensively,
taking into account important variables and market
intelligence. As a result, the forecasts are both conservative
and realistic and can be used with confidence in market planning
and evaluation of new business opportunities.
The
company's founder, Marvin Burns, has been active in the medical
industry and hospital community for over 20 years and has
prepared numerous market research reports that have been widely
distributed. The reports have served as a platform for
assessing new ventures and business opportunities across a broad
spectrum of products. Burns has also served as a consultant to
many of the major pharmaceutical and medical imaging companies
and venture groups in evaluating new product and market
opportunities.
BIO-TECH SYSTEMS has recently released the following market research reports. Click the links below to jump down and learn more.
Report #270: THE U.S. MARKET FOR DIAGNOSTIC RADIOPHARMACEUTICALS provides a comprehensive analysis of the markets for diagnostic radiopharmaceuticals. This considers the expiring patent for Cardiolite and the introduction of generic sestamibi. It also covers all aspects of nuclear cardiology, functional nuclear medicine, targeted oncology and PET imaging. This includes emerging applications in imaging myocardial infarction, congestive heart failure, in vivo infection imaging and new molecular imaging products for oncology. It also considers diagnostic applications in endocrine cancer, prostate cancer, breast cancer and multiple solid tumors. New molecular imaging and therapeutic modalities are being developed based on apoptosis, angiogenesis and PLE (Phospho-Lipid Ether) tumor targeting that will employ both SPECT and PET imaging. This will include new oncology products for diagnosing and monitoring cellular response to therapy. These molecular imaging platforms will also have therapeutic applications, increasing their versatility and usefulness Therapeutic radiopharmaceuticals will also employ molecular imaging to assess biodistribution and aid in developing patient specific dosimetry necessary for optimizing dosage and evaluating patient response to therapy. This stimulus to nuclear medicine will encourage more investment from biopharmaceutical companies and venture groups that will ultimately promote future market growth.
Report #260: THE U.S. MARKET FOR MEDICAL IMAGING CONTRAST MEDIA provides a comprehensive analysis of the markets for medical imaging contrast media in all modalities including X-ray, CT, MRI and ultrasound. Noninvasive vascular imaging will increase dramatically, replacing traditional angiography in many cases. New molecular imaging and therapeutic modalities are also being developed based on apoptosis, angiogenesis and imaging of growth receptors that are expressed in a large number of cancers. This will bring imaging modalities such as MRI, CT, PET and ultrasound closer together, increasing the sensitivity and specificity of diagnoses. Ultrasound contrast procedures will also become more productive, since clinicians and sonographers have implemented protocols that are simpler and more effective to use. There is also excellent likelihood that the approved indications for ultrasound contrast agents will be extended to perfusion imaging in the future. This technical influx will help all segments of the contrast media field and will stimulate more research and investment, adding strength and stability to newer venture companies as well as those more established in the field.
Report #240: THE MARKET FOR PET RADIOPHARMACEUTICALS & PET IMAGING analyzes the dynamic market for PET procedures and its effect as a driving force in molecular imaging. This has resulted in a rapid increase in the worldwide market for PET radiopharmaceuticals and growing demand for high performance PET scanners. The rapid increase in the market for PET-CT positions PET in the radiology mainstream where there is a large referral base. This will increase the demand for PET and help create new opportunities in molecular imaging as diagnosis and therapy become more unified. New clinical indications in oncology, as well as cardiology and neurology, will also offer a stimulus. This will promote growth of procedure volume and sales of FDG as well as development of new molecular PET tracers. It will also generate demand for high performance PET scanners, including the most sophisticated multi-slice PET-CT systems.
Report #230: THE WORLD MARKET FOR THERAPEUTIC RADIOPHARMACEUTICALS analyzes the markets for therapeutic radiopharmaceuticals including current and emerging applications for lymphoma, colon cancer, lung cancer, prostate cancer, breast cancer, endocrine cancer and other cancers resistant to traditional therapies. There has been a surge in research activity to expand applications for therapeutic radiopharmaceuticals employing more sophisticated targeting methodologies and more appropriate therapeutic isotopes for the tumors being treated. This has prompted increased interest in alpha emitters, where the shorter particle range and high-energy deposition can be used to advantage to destroy DNA directly, minimizing toxicity and protecting neighboring healthy cells. The growing use of molecular imaging is also helping to control and monitor dosage for increased safety and effectiveness. As these products enter the mainstream, there will be others in the pipeline for treating a variety of cancers. This will stimulate investment with greater support from large pharmaceutical companies. One motivator is the potential return on investment and the high price of these products, which is justified by their unique capabilities.
Report #170: THE U.S. MARKET FOR BRACHYTHERAPY PRODUCTS discusses the expanding market for brachytherapy products and analyzes sales prospects and future growth for prostate seed implants, endovascular radiation to inhibit restenosis, irradiated microsphere infusion for liver cancer, and post-surgical brachytherapy devices for brain cancer, breast cancer and many other cancers that can be treated locally. The positive performance of these devices will help maintain market growth, coupled with the rapid introduction of new technology and reduced regulatory delays.
Marvin Burns is president of BIO-TECH SYSTEMS, Inc., founded in 1980 to perform market research for companies in the healthcare field. Burns specializes in market evaluation, where technological and scientific insight is important. The company has prepared numerous market research reports on diagnostic and therapeutic radiopharmaceuticals, radiotherapy and immunotherapy products, brachytherapy, PET imaging, contrast agents, and interventional cardiology, which have been widely distributed. Burns has served as a consultant to many international firms and venture groups in strategic planning and development of new business opportunities. He has also been Technology Editor of Future Oncology, a publication widely circulated in the pharmaceutical and biotechnology industry, reporting on new developments in cancer diagnosis and treatment. Burns is a graduate of MIT and Harvard Business School’s advanced management program. He has over 100 publications and 15 patents and invention disclosures. Prior to forming BIO-TECH SYSTEMS, he was employed by firms in life sciences, bioinstrumentation and medical imaging fields in general management, marketing and product development. He was also a hospital administrator in charge of professional and technical services including medical imaging, clinical laboratories, therapy services, and materials management.
mburns_cv.doc
-OR-
mburns_cv.pdf
Back to Top
Send
this page to a friend